Rezolute appoints Daron Evans as CFO; receives UK Innovation Passport for RZ358

Rezolute, Inc.

Daron Evans appointed CFO, effective Jan 23, 2024; base salary $275,000, target bonus 50%.
Received inducement grant of 275,000 stock options at $1.02 (closing price), vesting over 4 years.
UK MHRA awarded Innovation Passport to RZ358 for congenital hyperinsulinism treatment.
Innovation Passport is entry to ILAP, aims to accelerate time to market and patient access.
Phase 3 study for RZ358 initiated; Phase 2 RZ402 data expected Q2 2024.

item 3.02 item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Daron Evans

Chief Financial Officer

RZLT · Rezolute, Inc.

Effective: 2024-01-23
Filed: January 29, 2024, 6:59 PM ET

On January 23, 2024, the Company’s Board of Directors approved the appointment of Mr. Evans, 50 years of age, to serve as the Company’s Chief Financial Officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Daron Evans was appointed as Chief Financial Officer at Rezolute, Inc..

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

On January 23, 2024, the Company’s Board of Directors approved the appointment of Mr. Evans, 50 years of age, to serve as the Company’s Chief Financial Officer.

View on SEC.gov

Rezolute, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-24-007811

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.